Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) shares traded down 4.7% on Monday . The company traded as low as $24.31 and last traded at $24.30. 491,801 shares changed hands during trading, a decline of 48% from the average session volume of 946,528 shares. The stock had previously closed at $25.50.
Analyst Ratings Changes
A number of research analysts recently weighed in on CLDX shares. The Goldman Sachs Group cut their price objective on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Celldex Therapeutics in a research report on Friday, June 13th. UBS Group lowered their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Morgan Stanley cut their price target on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $51.75.
View Our Latest Analysis on CLDX
Celldex Therapeutics Stock Performance
The company has a market capitalization of $1.63 billion, a P/E ratio of -8.13 and a beta of 1.22. The firm has a 50 day moving average price of $21.92 and a two-hundred day moving average price of $20.66.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. The firm had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.13 million. On average, equities analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.
Institutional Trading of Celldex Therapeutics
Several large investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its holdings in shares of Celldex Therapeutics by 171.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 881 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 501 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Celldex Therapeutics by 6,665.9% during the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 2,933 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at $121,000. Finally, Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics in the second quarter valued at about $125,000.
About Celldex Therapeutics
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access